278 related articles for article (PubMed ID: 12597338)
21. Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; Thompson KH; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):270-6. PubMed ID: 8402391
[TBL] [Abstract][Full Text] [Related]
22. Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
Yao J; Battell ML; McNeill JH
Can J Physiol Pharmacol; 1997 Feb; 75(2):83-90. PubMed ID: 9114928
[TBL] [Abstract][Full Text] [Related]
23. The effects of vanadium treatment on bone in diabetic and non-diabetic rats.
Facchini DM; Yuen VG; Battell ML; McNeill JH; Grynpas MD
Bone; 2006 Mar; 38(3):368-77. PubMed ID: 16256449
[TBL] [Abstract][Full Text] [Related]
24. Bis(maltolato)oxovanadium(IV) (BMOV) Attenuates Apoptosis in High Glucose-Treated Cardiac Cells and Diabetic Rat Hearts by Regulating the Unfolded Protein Responses (UPRs).
Cong XQ; Piao MH; Li Y; Xie L; Liu Y
Biol Trace Elem Res; 2016 Oct; 173(2):390-8. PubMed ID: 26983714
[TBL] [Abstract][Full Text] [Related]
25. Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
Thompson KH; Chiles J; Yuen VG; Tse J; McNeill JH; Orvig C
J Inorg Biochem; 2004 May; 98(5):683-90. PubMed ID: 15134913
[TBL] [Abstract][Full Text] [Related]
26. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
[TBL] [Abstract][Full Text] [Related]
27. Biochemical activity and morphology of the Golgi apparatus in alloxan diabetic rats.
Korkowiak A; Sarnecka-Keller M; Kaczmarski F
Folia Histochem Cytochem (Krakow); 1978; 16(2):89-96. PubMed ID: 149054
[TBL] [Abstract][Full Text] [Related]
28. Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1993; 71(3-4):263-9. PubMed ID: 8402390
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
Yuen VG; Orvig C; McNeill JH
Can J Physiol Pharmacol; 1995 Jan; 73(1):55-64. PubMed ID: 7600453
[TBL] [Abstract][Full Text] [Related]
30. Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
Yuen VG; Orvig C; McNeill JH
Am J Physiol; 1997 Jan; 272(1 Pt 1):E30-5. PubMed ID: 9038848
[TBL] [Abstract][Full Text] [Related]
31. A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
Winter CL; Lange JS; Davis MG; Gerwe GS; Downs TR; Peters KG; Kasibhatla B
Exp Biol Med (Maywood); 2005 Mar; 230(3):207-16. PubMed ID: 15734724
[TBL] [Abstract][Full Text] [Related]
32. A new salicylic acid-derivatized kojic acid vanadyl complex: synthesis, characterization and anti-diabetic therapeutic potential.
Wei Y; Zhang C; Zhao P; Yang X; Wang K
J Inorg Biochem; 2011 Aug; 105(8):1081-5. PubMed ID: 21726771
[TBL] [Abstract][Full Text] [Related]
33. Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
Thompson KH; Liboiron BD; Sun Y; Bellman KD; Setyawati IA; Patrick BO; Karunaratne V; Rawji G; Wheeler J; Sutton K; Bhanot S; Cassidy C; McNeill JH; Yuen VG; Orvig C
J Biol Inorg Chem; 2003 Jan; 8(1-2):66-74. PubMed ID: 12459900
[TBL] [Abstract][Full Text] [Related]
34. Protective effects of melatonin and aminoguanidine on the cornea in streptozotocin-induced diabetic rats.
Gül M; Emre S; Eşrefoğlu M; Vard N
Cornea; 2008 Aug; 27(7):795-801. PubMed ID: 18650666
[TBL] [Abstract][Full Text] [Related]
35. Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
Wasan KM; Risovic V; Yuen VG; McNeill JH
J Trace Elem Med Biol; 2006; 19(4):251-8. PubMed ID: 16443173
[TBL] [Abstract][Full Text] [Related]
36. Coordination chemistry and insulin-enhancing behavior of vanadium complexes with maltol C6H6O3 structural isomers.
Saatchi K; Thompson KH; Patrick BO; Pink M; Yuen VG; McNeill JH; Orvig C
Inorg Chem; 2005 Apr; 44(8):2689-97. PubMed ID: 15819554
[TBL] [Abstract][Full Text] [Related]
37. Chronic salt loading and cardiovascular-associated changes in experimental diabetes in rats.
Maeda C; Schaan B; Oliveira E; Oliveira V; De Angelis K; Irigoyen M
Clin Exp Pharmacol Physiol; 2007 Jul; 34(7):574-80. PubMed ID: 17581211
[TBL] [Abstract][Full Text] [Related]
38. Anti-diabetic effects of vanadium(III, IV, V)-chlorodipicolinate complexes in streptozotocin-induced diabetic rats.
Li M; Ding W; Smee JJ; Baruah B; Willsky GR; Crans DC
Biometals; 2009 Dec; 22(6):895-905. PubMed ID: 19404749
[TBL] [Abstract][Full Text] [Related]
39. In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
Marzban L; Bhanot S; McNeill JH
Mol Cell Biochem; 2001 Jul; 223(1-2):147-57. PubMed ID: 11681716
[TBL] [Abstract][Full Text] [Related]
40. Sarcoplasmic reticulum calcium ATPase is inhibited by organic vanadium coordination compounds: pyridine-2,6-dicarboxylatodioxovanadium(V), BMOV, and an amavadine analogue.
Aureliano M; Henao F; Tiago T; Duarte RO; Moura JJ; Baruah B; Crans DC
Inorg Chem; 2008 Jul; 47(13):5677-84. PubMed ID: 18510311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
